BACKGROUND AND PURPOSE: Several anti-angiogenic cancer drugs that inhibit VEGF receptor (VEGFR) signalling for efficacy are associated with a 15-60% incidence of hypertension. Tyrosine kinase inhibitors (TKIs) that have off-target activity at VEGFR-2 may also cause blood pressure elevation as an undesirable side effect. Therefore, the ability to translate VEGFR-2 off-target potency into blood pressure elevation would be useful in development of novel TKIs. Here, we have sought to quantify the relationship between VEGFR-2 inhibition and blood pressure elevation for a range of kinase inhibitors. EXPERIMENTAL APPROACH: Porcine aortic endothelial cells overexpressing VEGFR-2 (PAE) were used to determine IC50 for VEGFR-2 phosphorylation. These IC50 values were compared with published reports of exposure attained during clinical use and the corresponding incidence of all-grade hypertension. Unbound average plasma concentration (Cav,u ) was selected to be the most appropriate pharmacokinetic parameter. The pharmacokinetic-pharmacodynamic (PKPD) relationship for blood pressure elevation was investigated for selected kinase inhibitors, using data derived either from clinical papers or from rat telemetry experiments. KEY RESULTS: All-grade hypertension was predominantly observed when the Cav,u was >0.1-fold of the VEGFR-2 (PAE) IC50 . Furthermore, based on the PKPD analysis, an exposure-dependent blood pressure elevation >1 mmHg was observed only when the Cav,u was >0.1-fold of the VEGFR-2 (PAE) IC50 . CONCLUSIONS AND IMPLICATIONS: Taken together, these data show that the risk of blood pressure elevation is proportional to the amount of VEGFR-2 inhibition, and a margin of >10-fold between VEGFR-2 IC50 and Cav,u appears to confer a minimal risk of hypertension.
BACKGROUND AND PURPOSE: Several anti-angiogenic cancer drugs that inhibit VEGF receptor (VEGFR) signalling for efficacy are associated with a 15-60% incidence of hypertension. Tyrosine kinase inhibitors (TKIs) that have off-target activity at VEGFR-2 may also cause blood pressure elevation as an undesirable side effect. Therefore, the ability to translate VEGFR-2 off-target potency into blood pressure elevation would be useful in development of novel TKIs. Here, we have sought to quantify the relationship between VEGFR-2 inhibition and blood pressure elevation for a range of kinase inhibitors. EXPERIMENTAL APPROACH: Porcine aortic endothelial cells overexpressing VEGFR-2 (PAE) were used to determine IC50 for VEGFR-2 phosphorylation. These IC50 values were compared with published reports of exposure attained during clinical use and the corresponding incidence of all-grade hypertension. Unbound average plasma concentration (Cav,u ) was selected to be the most appropriate pharmacokinetic parameter. The pharmacokinetic-pharmacodynamic (PKPD) relationship for blood pressure elevation was investigated for selected kinase inhibitors, using data derived either from clinical papers or from rat telemetry experiments. KEY RESULTS: All-grade hypertension was predominantly observed when the Cav,u was >0.1-fold of the VEGFR-2 (PAE) IC50 . Furthermore, based on the PKPD analysis, an exposure-dependent blood pressure elevation >1 mmHg was observed only when the Cav,u was >0.1-fold of the VEGFR-2 (PAE) IC50 . CONCLUSIONS AND IMPLICATIONS: Taken together, these data show that the risk of blood pressure elevation is proportional to the amount of VEGFR-2 inhibition, and a margin of >10-fold between VEGFR-2 IC50 and Cav,u appears to confer a minimal risk of hypertension.
Authors: Richard M Steingart; George L Bakris; Helen X Chen; Ming-Hui Chen; Thomas Force; S Percy Ivy; Carl V Leier; Glenn Liu; Daniel Lenihan; JoAnn Lindenfeld; Michael L Maitland; Scot C Remick; W H Wilson Tang Journal: Am Heart J Date: 2012-02 Impact factor: 4.749
Authors: Gerald S Falchook; Georgina V Long; Razelle Kurzrock; Kevin B Kim; H-Tobias Arkenau; Michael P Brown; Omid Hamid; Jeffrey R Infante; Michael Millward; Anna Pavlick; Melvin T Chin; Steven J O'Day; Samuel C Blackman; C Martin Curtis; Peter Lebowitz; Bo Ma; Daniele Ouellet; Richard F Kefford Journal: Clin Cancer Res Date: 2014-06-23 Impact factor: 12.531
Authors: Feng R Luo; Zheng Yang; Amy Camuso; Richard Smykla; Kelly McGlinchey; Krista Fager; Christine Flefleh; Stephen Castaneda; Ivan Inigo; David Kan; Mei-Li Wen; Robert Kramer; Anne Blackwood-Chirchir; Francis Y Lee Journal: Clin Cancer Res Date: 2006-12-01 Impact factor: 12.531
Authors: Feng R Luo; Zheng Yang; Huijin Dong; Amy Camuso; Kelly McGlinchey; Krista Fager; Christine Flefleh; David Kan; Ivan Inigo; Stephen Castaneda; Tai W Wong; Robert A Kramer; Robert Wild; Francis Y Lee Journal: Clin Cancer Res Date: 2005-08-01 Impact factor: 12.531
Authors: Teresa Collins; Kelly Gray; Michal Bista; Matt Skinner; Christopher Hardy; Haiyun Wang; Jerome T Mettetal; Alexander R Harmer Journal: Br J Pharmacol Date: 2018-01-18 Impact factor: 8.739
Authors: Claire M Patterson; Srividya B Balachander; Iain Grant; Petar Pop-Damkov; Brian Kelly; William McCoull; Jeremy Parker; Michael Giannis; Kathryn J Hill; Francis D Gibbons; Edward J Hennessy; Paul Kemmitt; Alexander R Harmer; Sonya Gales; Stuart Purbrick; Sean Redmond; Matthew Skinner; Lorraine Graham; J Paul Secrist; Alwin G Schuller; Shenghua Wen; Ammar Adam; Corinne Reimer; Justin Cidado; Martin Wild; Eric Gangl; Stephen E Fawell; Jamal Saeh; Barry R Davies; David J Owen; Marianne B Ashford Journal: Commun Biol Date: 2021-01-25